Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 18/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053370 | 0.91 | KCNH2 (0.83) | AOC3KCNH2 | |
| SCHEMBL16053357 | 0.89 | AOC3 (0.81) | AOC3KCNH2 | |
| SCHEMBL16047409 | 0.89 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL30025643 | 0.88 | KCNH2 (1.00) | AOC3KCNH2 | |
| SCHEMBL16049446 | 0.88 | KCNH2 (1.00) | AOC3KCNH2 | |
| SCHEMBL20913192 | 0.87 | KCNH2 (0.73) | AOC3KCNH2 | |
| SCHEMBL16052898 | 0.82 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL17336342 | 0.82 | AOC3 (0.82) | AOC3KCNH2 | |
| SCHEMBL16048114 | 0.82 | KCNH2 (1.00) | AOC3KCNH2 | |
| SCHEMBL30026427 | 0.82 | KCNH2 (1.00) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | claimed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | claimed |
| CN-111032029-A | Vascular adhesion protein-1 inhibitors for the prevention or treatment of migraine | 普罗克斯马根有限责任公司 | 2020-04-17 | — | — | CN | claimed |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2019-10-01 | — | — | US | claimed |
| EP-2970260-B1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LLC (US) | 2019-04-24 | — | — | EP | claimed |
| EP-2970260-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | Proximagen Limited (GB) | 2016-01-20 | — | — | EP | claimed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | claimed |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PROXIMAGEN LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PNPO, XDH, EPX | AOC3 12/4885KCNH2 315/4885 |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | AOC3 10/4885KCNH2 364/4885 |
| US-20140275040-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | AOC3 133/4885KCNH2 4546/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | AOC3 7/4885KCNH2 448/4885 |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PNPO, XDH, EPX | AOC3 12/4885KCNH2 315/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | AOC3 7/4885KCNH2 448/4885 |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | AOC3 4/4885KCNH2 1505/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | AOC3 85/4885KCNH2 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.